310 related articles for article (PubMed ID: 17205319)
21. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Crespo-Facorro B; Rodríguez-Sánchez JM; Pérez-Iglesias R; Mata I; Ayesa R; Ramirez-Bonilla M; Martínez-Garcia O; Vázquez-Barquero JL
J Clin Psychiatry; 2009 Apr; 70(5):717-29. PubMed ID: 19389335
[TBL] [Abstract][Full Text] [Related]
22. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality.
Donath F; Quispe S; Diefenbach K; Maurer A; Fietze I; Roots I
Pharmacopsychiatry; 2000 Mar; 33(2):47-53. PubMed ID: 10761819
[TBL] [Abstract][Full Text] [Related]
23. The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia.
Walsh JK; Deacon S; Dijk DJ; Lundahl J
Sleep; 2007 May; 30(5):593-602. PubMed ID: 17552374
[TBL] [Abstract][Full Text] [Related]
24. Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration.
Morrens M; Wezenberg E; Verkes RJ; Hulstijn W; Ruigt GS; Sabbe BG
J Clin Psychopharmacol; 2007 Feb; 27(1):15-21. PubMed ID: 17224707
[TBL] [Abstract][Full Text] [Related]
25. Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.
Apiquian R; Fresán A; Herrera K; Ulloa RE; Lóyzaga C; de la Fuente-Sandoval C; Gutiérrez D; Nicolini H
Int J Neuropsychopharmacol; 2003 Dec; 6(4):403-8. PubMed ID: 14604455
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial.
Agar MR; Lawlor PG; Quinn S; Draper B; Caplan GA; Rowett D; Sanderson C; Hardy J; Le B; Eckermann S; McCaffrey N; Devilee L; Fazekas B; Hill M; Currow DC
JAMA Intern Med; 2017 Jan; 177(1):34-42. PubMed ID: 27918778
[TBL] [Abstract][Full Text] [Related]
27. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities.
Saletu B; Frey R; Krupka M; Anderer P; Grünberger J; See WR
Sleep; 1991 Oct; 14(5):439-47. PubMed ID: 1836894
[TBL] [Abstract][Full Text] [Related]
28. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.
Hsu WY; Huang SS; Lee BS; Chiu NY
J Clin Psychopharmacol; 2010 Jun; 30(3):230-4. PubMed ID: 20473056
[TBL] [Abstract][Full Text] [Related]
29. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
30. Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine.
Uchida S; Kato Y; Hirano K; Kagawa Y; Yamada S
Life Sci; 2007 Apr; 80(17):1635-40. PubMed ID: 17316700
[TBL] [Abstract][Full Text] [Related]
31. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
32. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
33. Caffeine attenuates waking and sleep electroencephalographic markers of sleep homeostasis in humans.
Landolt HP; Rétey JV; Tönz K; Gottselig JM; Khatami R; Buckelmüller I; Achermann P
Neuropsychopharmacology; 2004 Oct; 29(10):1933-9. PubMed ID: 15257305
[TBL] [Abstract][Full Text] [Related]
34. A pharmaco-EEG study on antipsychotic drugs in healthy volunteers.
Yoshimura M; Koenig T; Irisawa S; Isotani T; Yamada K; Kikuchi M; Okugawa G; Yagyu T; Kinoshita T; Strik W; Dierks T
Psychopharmacology (Berl); 2007 May; 191(4):995-1004. PubMed ID: 17333135
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
36. The effect of fluoxetine on sleep: a longitudinal, double-blind polysomnographic study of healthy volunteers.
Vasar V; Appelberg B; Rimón R; Selvaratnam J
Int Clin Psychopharmacol; 1994 Sep; 9(3):203-6. PubMed ID: 7814830
[TBL] [Abstract][Full Text] [Related]
37. Effects of some antipsychotics and a benzodiazepine hypnotic on the sleep-wake pattern in an animal model of schizophrenia.
Ishida T; Obara Y; Kamei C
J Pharmacol Sci; 2009 Sep; 111(1):44-52. PubMed ID: 19721330
[TBL] [Abstract][Full Text] [Related]
38. Sleep stage transitions in healthy humans altered by central monoaminergic antagonist.
Kishi A; Yasuda H; Matsumoto T; Inami Y; Horiguchi J; Struzik ZR; Yamamoto Y
Methods Inf Med; 2010; 49(5):458-61. PubMed ID: 20490423
[TBL] [Abstract][Full Text] [Related]
39. Effects of alcohol on polysomnographically recorded sleep in healthy subjects.
Feige B; Gann H; Brueck R; Hornyak M; Litsch S; Hohagen F; Riemann D
Alcohol Clin Exp Res; 2006 Sep; 30(9):1527-37. PubMed ID: 16930215
[TBL] [Abstract][Full Text] [Related]
40. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.
Crespo-Facorro B; Roiz-Santiáñez R; Pérez-Iglesias R; Pelayo-Terán JM; Rodríguez-Sánchez JM; Tordesillas-Gutiérrez D; Ramírez M; Martínez O; Gutiérrez A; de Lucas EM; Vázquez-Barquero JL
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1936-43. PubMed ID: 18930104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
